Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | celine.gongora |
|---|---|
| Group name | EquipeCG |
| Item Type | Attachment |
| Title | Texte intégral |
| URL | https://link.springer.com/content/pdf/10.1007/s00262-021-02973-w.pdf |
| Accessed | 2022/08/29 - 17:37:17 |
| Date Added | 2022/08/29 - 15:37:17 |
| Date Modified | 2022/08/29 - 15:37:17 |
| Parent item | First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de